XML 30 R20.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 12 - Segment Information
 9 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Segment Reporting Disclosure [Text Block]

Note 12. Segment Information

 

The following tables set forth our segment information:

 

   

Three Months Ended December 31,

    

Nine Months Ended December 31,

  
   

2023

    

2022

    

2023

    

2022

  

Revenues:

                                

Sterilization and Disinfection Control

   $ 19,338     $ 16,283     $ 52,345     $ 48,021  

Clinical Genomics

     12,546       15,585       41,464       48,525  

Biopharmaceutical Development

     9,430       11,646       28,526       34,757  

Calibration Solutions

     12,159       10,773       34,948       32,186  

Total revenues (a)

   $ 53,473     $ 54,287     $ 157,283     $ 163,489  
                                 

Gross profit:

                                

Sterilization and Disinfection Control

   $ 13,951     $ 11,614     $ 38,018     $ 34,581  

Clinical Genomics

     6,449       8,045       20,904       26,535  

Biopharmaceutical Development

     5,841       7,359       17,783       21,993  

Calibration Solutions

     7,212       5,740       20,050       17,411  

Reportable segment gross profit

     33,453       32,758       96,755       100,520  

Corporate and Other (b)

     (51 )     7       (61 )     (28 )

Gross profit

   $ 33,402     $ 32,765     $ 96,694     $ 100,492  

Reconciling Items:

                                

Operating expense

     33,469       29,363       97,485       97,689  

Operating (loss) income

     (67 )     3,402       (791 )     2,803  

Nonoperating (income) expense, net

     (2,013 )     1,486       (475 )     2,915  

Earnings (loss) before income taxes

   $ 1,946     $ 1,916     $ (316 )   $ (112 )

 

 

(a)

Intersegment revenues are not significant and are eliminated to arrive at consolidated totals.
 

(b)

 Unallocated corporate expenses are reported within Corporate and Other. 

 

The following table sets forth inventories by reportable segment. Our chief operating decision maker is not provided with any other segment asset information.

 

   

December 31,

    

March 31,

  
   

2023

    

2023

  

Sterilization and Disinfection Control

   $ 7,593     $ 3,492  

Clinical Genomics

     11,529       13,985  

Biopharmaceutical Development

     8,183       8,384  

Calibration Solutions

     8,668       8,781  

Total inventories

   $ 35,973     $ 34,642  

 

Inventories from GKE total $4,077 as of December 31, 2023, net of $412 fair value amortization step-up recorded during the three months ended December 31, 2023. GKE inventories are included in our Sterilization and Disinfection Control division.